{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:50Z","timestamp":1793924510160,"version":"4.8.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clindermatol.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:40:49Z","timestamp":1593218449000},"page":"660-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cutaneous immune-related adverse events to checkpoint inhibitors"],"prefix":"10.1016","volume":"38","author":[{"given":"Neeta","family":"Malviya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Tattersall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allireza","family":"Alloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.06.011_bb0005","doi-asserted-by":"crossref","first-page":"355.e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fonc.2018.00405","article-title":"Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet B phototherapy","volume":"8","author":"Donaldson","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0020","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0025","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0035","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3389\/fimmu.2018.01774","article-title":"Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy","volume":"9","author":"Yao","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0040","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0045","author":"Squibb"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0050","author":"Squibb"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0055","author":"Regeneron"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0060","author":"Genentech"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0065","author":"Serono"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0070","author":"AstraZeneca"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0075","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0080","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0085","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12094-018-1953-x","article-title":"Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology","volume":"21","author":"Gr\u00e1valos","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0090","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0100","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0120","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMc1805637","article-title":"PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist","volume":"379","author":"Kwatra","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0135","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0145","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.clindermatol.2020.06.011_bb0150","doi-asserted-by":"crossref","DOI":"10.5070\/D3247040915","article-title":"Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma","volume":"24","author":"Alniemi","year":"2018","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0165","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0170","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0180","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0185","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review","volume":"10","author":"De Bock","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0205","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.cgh.2016.09.017","article-title":"Nivolumab-induced colitis treated by infliximab","volume":"15","author":"Yanai","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4292\/wjgpt.v10.i1.29","article-title":"Ipilimumab and nivolumab induced steroid-refractory colitis treated with infliximab: a case report","volume":"10","author":"Nassri","year":"2019","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0215","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0230","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ced.13867","article-title":"Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers","volume":"44","author":"Liu","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0240","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.15354","article-title":"A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma","volume":"178","author":"Wolner","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0250","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0255","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamadermatol.2017.1679","article-title":"Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma","volume":"153","author":"Nakamura","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0260","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1684\/ejd.2017.3096","article-title":"Nivolumab-induced vitiligo successfully treated with narrowband UVB phototherapy","volume":"27","author":"Miyagawa","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0265","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: a systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0270","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0275","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0280","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jaad.2018.09.038","article-title":"Bullae for you: the increasing importance and implications of drug-induced bullous pemphigoid","volume":"79","author":"Heymann","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0285","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0290","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamadermatol.2013.756","article-title":"Bullous pemphigoid as pruritus in the elderly: a common presentation","volume":"149","author":"Bakker","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0295","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0300","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0305","first-page":"742","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma","volume":"15","author":"Schmidgen","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0310","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0315","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0320","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0325","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0330","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0335","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0340","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0345","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0355","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0360","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0365","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CMR.0000000000000397","article-title":"Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils","volume":"27","author":"Zhao","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0370","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0380","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jdcr.2018.11.017","article-title":"Nivolumab-associated DRESS syndrome: a case report","volume":"5","author":"Lu","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0390","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0395","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0400","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2018.05.031","article-title":"Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient","volume":"13","author":"Haratake","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0405","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000492172","article-title":"Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma","volume":"10","author":"Chirasuthat","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0410","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0415","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5348\/ijcri-201651-CR-10639","article-title":"A case of Stevens-Johnson syndrome in a patient on ipilimumab","volume":"7","author":"Pathria","year":"2016","journal-title":"Int J Case Rep Imag"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0420","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0425","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0430","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","article-title":"Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma","volume":"4","author":"Griffin","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0435","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0440","first-page":"E15","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis","volume":"101","author":"Woolridge","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0445","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review","volume":"31","author":"Zhang","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2340\/00015555-2566","article-title":"Development of papulopustular rosacea during nivolumab therapy for metastatic cancer","volume":"97","author":"Bousquet","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0455","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform rash induced by EGFR inhibitors: review of the literature and new insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2020.06.011_bb0460","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0465","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jdcr.2016.06.012","article-title":"Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma","volume":"2","author":"Mutgi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0470","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0475","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jdcr.2018.03.013","article-title":"Nivolumab-induced systemic vasculitis","volume":"4","author":"Kang","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0480","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0485","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jdcr.2018.05.020","article-title":"Checkpoint inhibitor-associated cutaneous small vessel vasculitis","volume":"4","author":"Castillo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0495","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","article-title":"Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report","volume":"66","author":"Owonikoko","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0500","doi-asserted-by":"crossref","first-page":"MMT10","DOI":"10.2217\/mmt-2018-0004","article-title":"Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations","volume":"5","author":"Grant","year":"2018","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0505","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1080\/0284186X.2018.1479069","article-title":"Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients","volume":"57","author":"Smedman","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0510","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/postgradmedj-2018-136081","article-title":"Immune checkpoint inhibitors in the management of malignancies in transplant recipients","volume":"94","author":"Regalla","year":"2018","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0515","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0520","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0525","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0530","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0535","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0545","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12094-018-1981-6","article-title":"Cancer immunotherapy of patients with HIV infection","volume":"21","author":"Gonzalez-Cao","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0550","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer","volume":"13","author":"Ostios-Garcia","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0555","first-page":"5985131","article-title":"A rare case of pembrolizumab-induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"issue":"4","key":"10.1016\/j.clindermatol.2020.06.011_bb0560","doi-asserted-by":"crossref","DOI":"10.4172\/2165-7920.1000951","article-title":"Seroconversion of Hbsag in melanoma patient with hepatitis B treated with checkpoint inhibitors: a case report","volume":"7","author":"Wen","year":"2017","journal-title":"J Clin Case Rep"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2020.06.011_bb0565","article-title":"2226. Immune checkpoint inhibitors in solid tumor patients with chronic hepatitis C virus infection: a prospective case-series","volume":"5","author":"Hosry","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0570","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2020.06.011_bb0575","first-page":"1","article-title":"Case report of a pregnancy during ipilimumab therapy","volume":"4","author":"Mehta","year":"2018","journal-title":"J Glob Oncol"},{"issue":"11","key":"10.1016\/j.clindermatol.2020.06.011_bb0580","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20301449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20301449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:16:36Z","timestamp":1760033796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20301449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0738081X20301449"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.011","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous immune-related adverse events to checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}